E2F1 and urinary bladder cancer: In a word, SLC16A1-AS1 in bladder cancer is implicated in several key aspects of cancer progression, particularly through its role in metabolic reprogramming, invasion, and proliferation, mediated by its interaction with E2F1 and MCT1.